TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) - Regional Cancer Care Associates LLC

Clinical Trials

TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung
Locations
East Brunswick
Sponsor
Clovis Oncology
Protocol Number
CO-1686-020
Cancer Diagnosis
Non-Small Cell Lung Cancer
To Learn More Call
201-510-0910